Gemcitabine + Nab-paclitaxel or Gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a real-world AGEO study (Jan, 10.1038/s41416-022-01713-w, 2022)

被引：0
|
作者：
Zaibet, Sonia
Hautefeuille, Vincent
Auclin, Edouard
Lievre, Astrid
Tougeron, David
Sarabi, Mathieu
Gilabert, Marine
Wasselin, Julie
Edeline, Julien
Artru, Pascal
Bechade, Dominique
Morin, Clemence
Ducoulombier, Agnes
Taieb, Julien
Pernot, Simon
机构：
[1] Université de Paris,Department of Hepato
[2] SIRIC CARPEM Comprehensive Cancer Center,Gastroenterology and Gastrointestinal Oncology, Hôpital Européen Georges Pompidou
[3] CHU Amiens Picardie,Department of Hepato
[4] Université de Paris,Gastroenterology and Gastrointestinal Oncology
[5] SIRIC CARPEM Comprehensive Cancer Center,Department of Medical Oncology, Hôpital Européen Georges Pompidou
[6] Université de Paris,INSERM, UMR 1138, team 22, Centre de Recherche des Cordeliers
[7] CHU Rennes,Department of Gastroenterology
[8] INSERM U1242,Department of Hepato
[9] CHU Poitiers,Gastroenterology
[10] Centre Léon Bérard,Department of Medical Oncology
[11] Institut Paoli-Calmettes,Department of Medical Oncology
[12] Centre Eugène Marquis,Department of Medical Oncology
[13] Hôpital Privé Jean Mermoz,Department of Hepato
[14] Institut Bergonié,Gastroenterology
[15] Centre Antoine Lacassagne,Department of Medical Oncology
来源：
BRITISH JOURNAL OF CANCER | 2022年 / 126卷 / 06期
关键词：
D O I：
10.1038/s41416-022-01734-5
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：969 / 969
页数：1
相关论文
共 50 条
  • [21] FOLFIRINOX for advanced pancreatic cancer patients after nab-paclitaxel plus gemcitabine failure: retrospective analysis
    Matsumoto, Toshihiko
    Kimura, Shogo
    Himei, Hitomi
    Okazaki, Ukyo
    Kurioka, Yusuke
    Tsuduki, Takao
    Takagi, Shijiro
    Takatani, Masahiro
    Hiramatsu, Ysushi
    Morishita, Hirofumi
    ANNALS OF ONCOLOGY, 2019, 30
  • [22] Could the combination of Nab-paclitaxel plus gemcitabine salvage metastatic pancreatic adenocarcinoma after folfirinox failure? A single institutional retrospective analysis
    El Rassy, Elie
    Assi, Tarek
    El Karak, Fadi
    Ghosn, Marwan
    Kattan, Joseph
    CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2017, 41 (02) : E26 - E28
  • [23] Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX
    Vreeland, Timothy J.
    McAllister, Florencia
    Javadi, Sanaz
    Prakash, Laura R.
    Fogelman, David R.
    Ho, Linus
    Varadhachary, Gauri
    Aloia, Thomas A.
    Vauthey, Jean-Nicolas
    Lee, Jeffrey E.
    Kim, Michael P.
    Katz, Matthew H. G.
    Tzeng, Ching-Wei D.
    PANCREAS, 2019, 48 (06) : 837 - 843
  • [24] Real-world data comparing FOLFIRINOX versus gemcitabine nab-paclitaxel as first-line treatment of metastatic pancreatic ductal adenocarcinoma patients in the United States.
    Klein-Brill, Avital
    Amar-Farkash, Shlomit
    Lawrence, Gabriella
    Collisson, Eric Andrew
    Fisch, Michael Jordan
    Aran, Dvir
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16271 - E16271
  • [25] Phase Ib Study of Ulixertinib Plus Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma
    Grierson, Patrick M.
    Tan, Benjamin
    Pedersen, Katrina S.
    Park, Haeseong
    Suresh, Rama
    Amin, Manik A.
    Trikalinos, Nikolaos A.
    Knoerzer, Deborah
    Kreider, Brent
    Reddy, Anupama
    Liu, Jingxia
    Der, Channing J.
    Wang-Gillam, Andrea
    Lim, Kian-Huat
    ONCOLOGIST, 2023, 28 (02): : E115 - E123
  • [26] Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in advanced pancreatic cancer: a systematic review
    Chiorean, Elena Gabriela
    Cheung, Winston Y.
    Giordano, Guido
    Kim, George
    Al-Batran, Salah-Eddin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [27] Comparison of adjuvant nab-paclitaxel plus gemcitabine, S-1 and gemcitabine chemotherapy for resectable pancreatic cancer: a real-world study
    Li, Haorui
    Guo, Yu
    Sun, Xugang
    Lu, Yang
    Chang, Shaofei
    Wang, Xiuchao
    Gao, Song
    Gao, Chuntao
    Zhao, Tiansuo
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [28] FOLFIRINOX or gemcitabine/nab-paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision-making in real-world
    Marschner, Norbert
    Hegewisch-Becker, Susanna
    Reiser, Marcel
    von der Heyde, Eyck
    Bertram, Mathias
    Hollerbach, Stephan H.
    Kreher, Stephan
    Wolf, Thomas
    Binninger, Adrian
    Chiabudini, Marco
    Kaiser-Osterhues, Anja
    Jaenicke, Martina
    INTERNATIONAL JOURNAL OF CANCER, 2023, 152 (03) : 458 - 469
  • [29] The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence
    Prejac, Juraj
    Hamzic, Dora Tomek
    Librenjak, Niksa
    Gorsic, Irma
    Kekez, Domina
    Plestina, Stjepko
    MEDICINE, 2022, 101 (39) : E30566
  • [30] Outcomes in metastatic pancreatic adenocarcinoma (MPAC) patients treated with FOLFIRINOX (FFX)/FOLFOX(FX) and gemcitabine plus nab-paclitaxel (NabG).
    Schmidt, Shannon Leah
    Durkal, Vipal
    Jayavalsan, Shinoj Pattali
    Thomas, James P.
    Ritch, Paul S.
    Erickson, Beth
    Christians, Kathleen K.
    Tsai, Susan
    Evans, Douglas B.
    George, Ben
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
12345